Study summary · research use only
Bremelanotide: First Approval
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This article summarizes the regulatory milestones leading to the first approval of bremelanotide (Vyleesi), a melanocortin receptor agonist, in the USA for treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), characterized by low sexual desire causing marked distress or interpersonal difficulty. The authors describe it as a self-administered, on-demand subcutaneous therapy, initially developed by Palatin Technologies, which sponsored the Phase 3 clinical trials, and later out-licensed to AMAG Pharmaceuticals Inc. for exclusive North American development and commercialization rights, including submission of the New Drug Application to the US FDA. Bremelanotide is described as a synthetic peptide analogue of the neuropeptide hormone alpha melanocyte-stimulating hormone (α-MSH) with high affinity for the melanocortin type 4 receptor.
Abstract
Bremelanotide (Vyleesi™) is a melanocortin receptor agonist recently approved in the USA for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty. It is a self-administered, on-demand subcutaneous therapy. Initially developed by Palatin Technologies who sponsored the Phase 3 clinical trials, bremelanotide was subsequently out-licensed to AMAG Pharmaceuticals Inc. for exclusive North American rights to develop and commercialize the drug, including submitting the New Drug Application to the US FDA. Bremelanotide is a synthetic peptide analogue of the neuropeptide hormone alpha melanocyte-stimulating hormone (α-MSH) with high affinity for the melanocortin type 4 receptor (thought to be important for sexual function), giving it the potential to modulate brain pathways involved in sexual response. This article summarizes the milestones in the development of bremelanotide leading to this first regulatory approval.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.